ALJ Lord Finds Section 337 Violation In Certain Microfluidic Systems (337-TA-1100)

OM
Oblon, McClelland, Maier & Neustadt, L.L.P

Contributor

Oblon is among the largest US law firms that exclusively practice IP law. Businesses worldwide depend on Oblon to establish, protect and leverage their IP assets. Our team of 100+ legal professionals includes some of the country’s most respected practitioners. Most attorneys hold advanced degrees in engineering, physics, chemistry, biotechnology and other scientific disciplines. Oblon is headquartered within steps of the USPTO office in Alexandria, Virginia. 
Certain Microfluidic Systems, Components Thereof, and Products Containing the Same.
United States Intellectual Property

On July 12, 2019, ALJ Dee Lord issued a notice of Initial Determination on Violation in Certain Microfluidic Systems, Components Thereof, and Products Containing the Same (Inv. No. 337-TA-1100).

By way of background, this investigation is based on a January 11, 2018 complaint filed by 10X Genomics, Inc. alleging violation of Section 337 by Bio-Rad Laboratories, Inc. of Hercules, California for unlawfully importing into the U.S., selling for importation, and/or selling within the U.S. after importation certain microfluidic systems, components thereof, and products containing the same that infringe one or more claims of U.S. Patent Nos. 9,644,204 (the '204 patent), 9,689,024 (the '024 patent), 9,695,468 (the '468 patent), and 9,856,530 (the '530 patent).

According to the Notice, ALJ Lord determined, inter alia, that a violation of Section 337 has occurred with respect to the '024 patent, the '468 patent, and the '530 patent, but that no violation has occurred in connection with the '204 patent.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More